SCHEMBL2811063

SCHEMBL2811063

O=C(CN1CCN(c2cnccn2)CC1)N1CCC(CNCc2ccccn2)(c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
LMNA P02545 2/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TACR1 P25103 3/20 0.42
KDM4E B2RXH2 4/20 0.41
TSHR P16473 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
ALOX12 P18054 1/20 0.41
MAPT P10636 3/20 0.41
PHGDH O43175 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NAMPT P43490 1/20 0.37
SRPK1 Q96SB4 1/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808354 0.91 ALDH1A1 (0.44) ALDH1A1LMNAHSD17B10L3MBTL1TACR1
SCHEMBL2809223 0.91 KDM4E (0.40) ALDH1A1LMNAHSD17B10L3MBTL1TACR1
SCHEMBL3134693 0.89 PHGDH (0.49) ALDH1A1LMNAHSD17B10L3MBTL1TACR1
SCHEMBL2806266 0.87 ALDH1A1 (0.41) ALDH1A1LMNAHSD17B10L3MBTL1TACR1
SCHEMBL2805236 0.87 KDM4E (0.40) ALDH1A1LMNAHSD17B10L3MBTL1TACR1
SCHEMBL2804840 0.87 SLC6A4 (0.47) ALDH1A1LMNAHSD17B10L3MBTL1TACR1
SCHEMBL4812086 0.87 KDM4E (0.42) ALDH1A1LMNAHSD17B10L3MBTL1TACR1
SCHEMBL2806018 0.86 KDM4E (0.40) ALDH1A1LMNAHSD17B10L3MBTL1TACR1
SCHEMBL2807139 0.86 KDM4E (0.40) ALDH1A1LMNAHSD17B10L3MBTL1TACR1
SCHEMBL2804770 0.86 KDM4E (0.40) ALDH1A1LMNAHSD17B10L3MBTL1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240670-A1 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2010-09-23 US disclosed
EP-1694668-B1 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2010-07-28 EP disclosed
EP-1694668-A1 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS Sanofi-Aventis (FR) 2006-08-30 EP disclosed
WO-2005054229-A1 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240670-A1 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION AQP4, AQP1, IL4I1 ALDH1A1 48/4885LMNA 2167/4885HSD17B10 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.